|
CA2119155C
(en)
*
|
1991-10-18 |
1999-06-15 |
Dennis Paul Phillion |
Fungicides for the control of take-all disease of plants
|
|
SE9703407D0
(sv)
*
|
1997-09-19 |
1997-09-19 |
Astra Ab |
New use
|
|
SE9802073D0
(sv)
|
1998-06-11 |
1998-06-11 |
Astra Ab |
New use
|
|
GB9825554D0
(en)
|
1998-11-20 |
1999-01-13 |
Smithkline Beecham Spa |
Novel Compounds
|
|
US7037922B1
(en)
|
2000-03-10 |
2006-05-02 |
Neurogen Corporation |
Aryl fused 2,4-disubstituted pyridines: NK3 receptor ligands
|
|
ATE247652T1
(de)
|
1999-03-29 |
2003-09-15 |
Neurogen Corp |
4-substituierte chinolinderivate als nk-3 und/oder gaba(a) rezeptor liganden
|
|
AU4802500A
(en)
*
|
1999-04-26 |
2000-11-10 |
Neurogen Corporation |
2-aminoquinolinecarboxamides: neurokinin receptor ligands
|
|
WO2002083663A1
(en)
*
|
2001-04-11 |
2002-10-24 |
Glaxosmithkline S.P.A. |
Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
|
|
WO2002089802A2
(en)
*
|
2001-05-08 |
2002-11-14 |
Schering Corporation |
Use of neurokinin receptor antagonists to treat androgen-dependent diseases
|
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
|
BRPI0407071B8
(pt)
|
2003-01-28 |
2021-05-25 |
Ironwood Pharmaceuticals Inc |
peptídeo purificado, seu método de produção e composição farmacêutica para o tratamento de distúrbios gastrointestinais
|
|
GB0303086D0
(en)
*
|
2003-02-11 |
2003-03-19 |
Merck Sharp & Dohme |
New compounds
|
|
GB0419192D0
(en)
|
2004-08-27 |
2004-09-29 |
Merck Sharp & Dohme |
Therapeutic agents
|
|
SG155229A1
(en)
*
|
2004-11-09 |
2009-09-30 |
Smithkline Beecham Corp |
Glycogen phosphorylase inhibitor compounds and pharmaceutical compositions thereof
|
|
GB0425077D0
(en)
*
|
2004-11-12 |
2004-12-15 |
Smithkline Beecham Corp |
Novel compounds
|
|
GB0515580D0
(en)
|
2005-07-29 |
2005-09-07 |
Merck Sharp & Dohme |
Therapeutic compounds
|
|
CN101282961A
(zh)
*
|
2005-08-11 |
2008-10-08 |
阿斯利康(瑞典)有限公司 |
作为nk3受体调节剂的烷基吡啶基喹啉
|
|
AR057130A1
(es)
|
2005-09-21 |
2007-11-14 |
Astrazeneca Ab |
Quinolinas de alquilsulfoxido y una composicion farmaceutica
|
|
TW200804288A
(en)
|
2005-12-12 |
2008-01-16 |
Astrazeneca Ab |
Alkylsulphonamide quinolines
|
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
|
DK2170930T3
(da)
|
2007-06-04 |
2012-11-05 |
Synergy Pharmaceuticals Inc |
Agonister af guanylatcyclase, anvendelige til behandlingen af gastrointestinale sygdomme, inflammation, cancer og andre sygdomme
|
|
JP2010540553A
(ja)
*
|
2007-09-28 |
2010-12-24 |
グラクソスミスクライン エルエルシー |
グリコーゲンホスホリラーゼ阻害剤化合物及びその医薬組成物
|
|
JP2010540552A
(ja)
*
|
2007-09-28 |
2010-12-24 |
グラクソスミスクライン エルエルシー |
グリコーゲンホスホリラーゼ阻害剤化合物及びその医薬組成物
|
|
EP2328910B1
(en)
|
2008-06-04 |
2014-08-06 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
|
ES2624828T3
(es)
|
2008-07-16 |
2017-07-17 |
Synergy Pharmaceuticals Inc. |
Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
|
|
WO2018129556A1
(en)
|
2017-01-09 |
2018-07-12 |
Ardelyx, Inc. |
Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
|
|
ES2657938T3
(es)
|
2008-12-31 |
2018-03-07 |
Ardelyx, Inc. |
Compuestos y métodos para inhibir el antipuerto mediado por NHE en el tratamiento de trastornos asociados a la retención de líquidos o a la sobrecarga de sales y trastornos del tracto gastrointestinal
|
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
|
EP2887964B1
(en)
|
2012-08-21 |
2019-07-03 |
Ardelyx, Inc. |
Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
|
|
US10376481B2
(en)
|
2012-08-21 |
2019-08-13 |
Ardelyx, Inc. |
Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
|
|
CA2905438A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
|
US9486494B2
(en)
|
2013-03-15 |
2016-11-08 |
Synergy Pharmaceuticals, Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
|
WO2014169094A2
(en)
|
2013-04-12 |
2014-10-16 |
Ardelyx, Inc |
Nhe3-binding compounds and methods for inhibiting phosphate transport
|
|
WO2014170648A1
(en)
|
2013-04-19 |
2014-10-23 |
Astrazeneca Ab |
A nk3 receptor antagonist compound (nk3ra) for use in a method for the treatment of polycystic ovary syndrome (pcos)
|
|
JP6606491B2
(ja)
|
2013-06-05 |
2019-11-13 |
シナジー ファーマシューティカルズ インコーポレイテッド |
グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法
|
|
WO2017072629A1
(en)
|
2015-10-29 |
2017-05-04 |
Cadila Healthcare Limited |
Pharmaceutical combination of nk3 receptor antagonist and biguanides
|
|
KR20240090875A
(ko)
|
2017-01-09 |
2024-06-21 |
알데릭스, 인코포레이티드 |
위장관 장애를 치료하는 데 유용한 화합물
|
|
WO2018129557A1
(en)
|
2017-01-09 |
2018-07-12 |
Ardelyx, Inc. |
Inhibitors of nhe-mediated antiport
|